Low Levels of Antiretroviral‐Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second‐Line Treatment | Zendy

Charles Kouanfack | Zendy; Céline Montavon | Zendy; Christian Laurent | Zendy; Avelin F. Aghokeng | Zendy; Alain Kenfack | Zendy; Anke Bourgeois | Zendy; Sinata KoullaShiro | Zendy; Eitel MpoudiNgolé | Zendy; Martine Peeters | Zendy; Éric Delaporte | Zendy

Open Access

Low Levels of Antiretroviral‐Resistant HIV Infection in a Routine Clinic in Cameroon that Uses the World Health Organization (WHO) Public Health Approach to Monitor Antiretroviral Treatment and Adequacy with the WHO Recommendation for Second‐Line Treatment

Author(s) -

Charles Kouanfack,

Céline Montavon,

Christian Laurent,

Avelin F. Aghokeng,

Alain Kenfack,

Anke Bourgeois,

Sinata KoullaShiro,

Eitel MpoudiNgolé,

Martine Peeters,

Éric Delaporte

Publication year - 2009

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/597779

Subject(s) - medicine , public health , human immunodeficiency virus (hiv) , drug resistance , cross sectional study , antiretroviral treatment , antiretroviral therapy , antiretroviral drug , hiv drug resistance , sida , viral disease , environmental health , virology , family medicine , viral load , pediatrics , nursing , pathology , microbiology and biotechnology , biology

A cross-sectional study, performed at a routine human immunodeficiency virus (HIV)/AIDS clinic in Cameroon that uses the World Health Organization public health approach, showed low rates of virological failure and drug resistance at 12 and 24 months after initiation of antiretroviral therapy. Importantly, the cross-sectional study also showed that the World Health Organization recommendation for second-line treatment would be effective in almost all patients with HIV drug resistance mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research